Alnylam Pharmaceuticals, Inc.
ALNYAlnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing RNA interference (RNAi) therapeutics to treat genetic, cardio-metabolic, liver, and neurological diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company pioneers the use of RNA interference technology to silence specific genes associated with various illnesses, aiming to address unmet medical needs.
Company News
The global amyloidosis therapeutics market is experiencing strong growth, valued at $2.95 billion in 2024 and expected to reach $6.37 billion by 2033 with a 9.20% CAGR. Growth is driven by accelerating ATTR cardiomyopathy diagnosis through imaging technologies, rapid uptake of disease-modifying therapies in North America, and expanded reimburseme...
Alnylam Pharmaceuticals announced its 'Alnylam 2030' five-year roadmap, targeting durable global leadership in transthyretin (TTR) diseases with plans to launch nucresiran by 2028-2030. The company projects 2026 net product revenue of $4.9-5.3 billion (71% growth), significantly above Street estimates, with TTR franchise expected to reach $4.4-4....
Scenic Biotech announced a license and research agreement with Ono Pharmaceutical to utilize its Cell-Seq platform for discovering novel therapeutic targets. This marks Scenic's fourth major pharmaceutical collaboration, joining existing partnerships with Genentech, Bristol Myers Squibb, and Alnylam.
Vertiv Holdings, an AI infrastructure company providing data center power and cooling solutions, has a 71% probability of being added to the S&P 500 in Q1 2026 according to prediction markets, significantly higher than competitors. The company has surged over 1,047% in less than three years with strong financial performance, including 29% year-ov...
